A listed Aussie company battling the Coronavirus

|

Published 03-FEB-2020 13:19 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

With the recent emergence in China of a new virulent strain of the Coronavirus, and the well-publicised impacts of that virus on human health, Zoono Group Limited (ASX:ZNO) has been inundated by public and shareholder enquiry concerning its products and their effectiveness in combatting the spread of the new virus.

The interest has been the catalyst for its shares rising 24% on Thursday to finish at 82 cents on $2.3 million stock traded.

The $142 million capped Zoono specialises in the development, manufacture and global distribution of a unique range of long-lasting and environmentally friendly antimicrobial solutions.

Zoono Group has developed, and owns, a wealth of intellectual property based around the ‘Zoono Molecule’ – a unique, antimicrobial technology that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould. It has proven efficacy and longevity, it does not leach and cannot diminish in strength.

The company believes it is well positioned to be part of the solution to both coronavirus and other new virus threats through its technology, particularly its longevity and killing methodology.

To put this into context, Zoono’s Z71 Microbe Shield Surface Sanitiser was successfully tested in 2014 against bovine coronavirus (i.e. a surrogate recognised by the World Health Organisation for other members of the coronaviridae family, including the MERS virus (CoV-MERS)). Test results confirmed a 99.99% efficacy in five minutes.

Zoono’s Z71 Microbe Shield Surface Sanitiser and GermFree24 Hand Sanitiser products were recently sent to a German laboratory for testing against the latest Chinese strain of the coronavirus (2019-nCoV). This strain of the coronavirus has not previously been available for testing.

Given the successful test results in 2014 and since, Zoono is confident that both products will have a level of efficacy against the current strain of the coronavirus similar to that achieved previously. Both contain the same active ingredient. Results from testing against the current coronavirus strain are expected in the next four to six weeks.

Operationally, once the impact of the new coronavirus emerged, Zoono made an immediate decision in early January to ramp up production of its key active ingredients and its Z71 Microbe Shield Surface Sanitiser and GermFree24 Hand Sanitiser finished goods.

This decision has proved to be very prescient as this month has seen:

  • Product orders in excess of NZ$1M received in the last two weeks of January, predominantly from China and Hong Kong
  • Online consumer sales up significantly with a record day recently of $49,000 in one day
  • Forward orders and product inquiries increasingly strong, with particular interest from major companies in new distribution arrangements and the introduction of Zoono products into different vertical markets Zoono expects to be able to meet the increased demand for its products.

Find out what other Australian Stock Exchange Biotechs are doing to combat COVID-19



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X